Navigation Links
Immune Design Corp. and Sanofi-Aventis Announce Research Collaboration
Date:10/26/2011

SEATTLE, Oct. 26, 2011 /PRNewswire/ -- Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease, cancer and allergy, announced today that it has entered into an early-stage research collaboration with Sanofi-Aventis to investigate the use of IDC's Glucopyranosyl Lipid Adjuvant (GLA) technology, a toll–like receptor 4 (TLR-4) agonist, in the field of allergy.

(Logo: http://photos.prnewswire.com/prnh/20111018/SF88252LOGO)

"We are excited to form this relationship with Sanofi," noted IDC CEO Carlos Paya, MD, Ph.D.  "The application of next-generation TLR-4 agonists able to shape the immune response in allergic disease has enormous therapeutic potential.  Our initial collaboration has the strong possibility to lead to a broader development focused partnership with Sanofi in the near future."

Under the agreement, IDC will provide access to the GLA technology, allowing Sanofi the ability to evaluate the biological and immunological properties of this TLR-4 agonist in vitro and in allergy disease models, and will be granted an option to select lead candidates for further development.  The terms have not been disclosed.    

IDC has advanced the GLA technology into early clinical stage development.  This technology can be used to promote optimal activation of human dendritic cells, has demonstrated compatibility with many antigens, and has a well-established safety profile to date.

Additional information can be found on the company's website at www.immunedesign.com.

Media Relations

Immune Design Corp.
Cassie Ostrander
Phone:  206-826-7901
E-mail:  media@immunedesign.com


'/>"/>
SOURCE Immune Design Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Immune Design Corp. Appoints Guy F. Cipriani as Chief Business Officer
2. Alcohol-related behavior changes -- blame your immune system
3. Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy
4. New HIV vaccine approach targets desirable immune cells
5. David H. Murdock Research Institute Assumes Control of the Immune Tolerance Institute and Establishes a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development
6. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
7. UCLA scientists discover new way to wake up the immune system using nano vaults to deliver drugs
8. Amgen and Xencor Enter Option Deal to Co-Develop Xencors Novel Antibody for Autoimmune Diseases
9. NIH scientists show how anthrax bacteria impair immune response
10. Immune Design Grants Adjuvant License to MedImmune
11. Adaptive TCR Launches the immunoSEQ™ Product Line - Visualizing the Immune System With Next-Generation Sequencing.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Whitehouse Labs ... Within Albany Molecular Research, Inc. (AMRI), the scientific staff dedicated to Extractables / ... planned for further growth in 2017. Extractable & Leachable evaluations have become increasingly ...
(Date:1/18/2017)... Gainesville, FL (PRWEB) , ... January 18, 2017 ... ... muscle weakness and paralysis, today announced that it has submitted a 510(k) to ... stationary bikes that utilize MYOLYN’s patent-pending functional electrical stimulation (FES) technology. , ...
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev ... for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers ... research issues such as trial performance metrics, patient enrollment diversity, protocol optimization, and ...
(Date:1/18/2017)... ... January 18, 2017 , ... uBiome, ... latest paper by its Science Editor, Dr. Elisabeth Bik, in the December 2016 ... Dr. Bik joined uBiome in October 2016 from her previous position at Stanford ...
Breaking Biology Technology:
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):